Learn More
BACKGROUND Liver damage is frequently seen in HIV-positive subjects, often resulting from coinfection with hepatitis B and/or C viruses (HCV), alcohol abuse, etc. However, the etiology of liver disease still remains unknown for a small subset of individuals. METHODS Cryptogenic liver disease (CLD) was defined as persistently elevated aminotransferases(More)
BACKGROUND It is unclear whether resistance to immunologic damage in long-term non-progressors (LTNP) will last indefinitely or whether it merely represents the extreme of a Gaussian distribution, and therefore progression will occur eventually. PATIENTS AND METHODS A cohort of 19 LTNP was established in 1997. Plasma viraemia and CD4 cell counts were(More)
BACKGROUND Human immunodeficiency virus type 1 (HIV-1), hepatitis B virus (HBV), human T-cell lymphotropic virus type 1 (HTLV-1) and Treponema pallidum represent major public health problems in sub-Saharan countries. These infections can be transmitted from mother to children and may cause severe morbidities in their offspring. Ethiopia is among the(More)
BACKGROUND Raltegravir has been shown to be active against wildtype HIV-2 with a phenotypic susceptibility similar to HIV-1. Due to the recent introduction of these novel inhibitors, information on the selection of resistance mutations and its phenotypic effect in this population is scarce. OBJECTIVES To explore in vitro the effect of raltegravir(More)
BACKGROUND Current protease inhibitors (PIs) are designed against HIV-1, and information on their performance against HIV-2 clinical isolates is scarce. METHODS Genetic and phenotypic analyses using all available PIs were performed in five HIV-2 primary isolates from two patients on regular follow-up who failed PI-HAART. RESULTS HIV-2 proteases before(More)
BACKGROUND Variables influencing serum hepatitis C virus (HCV) RNA levels and genotype distribution in individuals with human immunodeficiency virus (HIV) infection are not well known, nor are factors determining spontaneous clearance after exposure to HCV in this population. METHODS All HCV antibody (Ab)-positive patients with HIV infection in the(More)
BACKGROUND Human T-cell lymphotropic virus type I (HTLV-I) causes a subacute myelopathy in less than 5% of chronic carriers. However, the risk of neurologic disease appears to increase in persons infected through blood transfusion. METHODS We report three recipients of solid organ transplants who developed a subacute myelopathy within 2 years after(More)
HTLV-1=2 antenatal screening is not mandatory in European countries. The rapid increase in immigrants coming from areas endemic for HTLV-1 infection has compelled a review of this policy in Spain. From February 2006 to December 2007, a cross-sectional study was carried out in all pregnant women attended at 10 different Spanish hospitals. An enzyme(More)
Genetic sequence alignment of the transmembrane region from HIV-1 group O and HIV-2 isolates was performed to examine their potential susceptibility to fusion inhibitors enfuvirtide (T-20) and T-1249. A high genetic diversity within the HRI and HR2 domains was found, which should compromise any antiviral effect of T-20 on HIV-2 and HIV-1 group O viruses.(More)